MacroGenics (MGNX) vs Sionna Therapeutics (SION)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MacroGenics (MGNX) has outperformed Sionna Therapeutics (SION) over the past year, gaining 99.4% versus a loss of 82.8%. MacroGenics is the larger company by market cap ($226.1 million vs $221.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MGNX | SION |
|---|---|---|
| Share price | $3.55 | $4.90 |
| Market cap | $226.14M | $221.24M |
| 1-day change | 0.00% | +1.66% |
| YTD return | +120.50% | -88.09% |
| 1-year return | +99.44% | -82.81% |
| 5-year return | -82.02% | — |
| EPS (TTM) | $-1.70 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.08 | $54.97 |
| 52-week low | $1.29 | $4.01 |
| Distance from 52-week high | -30.12% | -91.09% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +125.35% | +328.57% |
| Average volume | 622.92K | 2.19M |
| Shares outstanding | 63.70M | 45.15M |
| Employees | 293 | 59 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGNX has outperformed SION by 182.2 percentage points over the past year.
About MacroGenics
MGNX stock →MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
About Sionna Therapeutics
SION stock →Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees
MGNX vs SION FAQ
Which is bigger, MacroGenics or Sionna Therapeutics?
MacroGenics (MGNX) is larger, with a market capitalization of $226.14M compared with $221.24M for Sionna Therapeutics (SION).
Which stock has performed better over the past year, MGNX or SION?
MGNX returned +99.44% over the past 12 months, compared with -82.81% for SION (price return, excluding dividends). Past performance does not predict future results.
Are MacroGenics and Sionna Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.